Calpastatin, a calpain specific inhibitor, reduce seizures in a mouse model of temporal lobe epilepsy
Epilepsia Open · 2025
DOI: 10.1002/epi4.70030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsia Open, 2025. Verfasst von Philip M Lam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Calcium-Binding Proteins, Calpain, Seizures, Epilepsy, Temporal Lobe. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Epilepsy is a chronic condition characterized by unpredictable and recurrent spontaneous seizures. In a previous study, we reported that pharmacological inhibition of calpain prevented epileptogenesis in the rat pilocarpine model. In this study, we demonstrate that transgenic overexpression of calpastatin, the endogenous inhibitor of calpain, reduces calpain activation and lessens seizure burden in the mouse intrahippocampal kainate model. Blockade of calpain activation was evidenced by a reduction in the generation of spectrin breakdown products, a hallmark of calpain activation. CAST overexpression was associated with a significant reduction in seizure burden, further supporting the idea that blocking calpain overactivation prevents epilepsy. Moreover, a reduction in seizure burden was accompanied by a decrease in inflammatory markers but not cell death. Together, these observations corroborate the role of calpain overactivation in epileptogenesis and provide further support for the use of calpain inhibitors as a viable strategy to prevent epilepsy. Plain Language Summary The mechanisms by which brain alterations lead to spontaneous seizures are not well understood. Acquired epilepsy often follows brain trauma. After a brain injury, the activation of the protease calpain has been associated with the development of spontaneous seizures. Our observations indicate that transgenic overexpression of calpastatin, an endogenous inhibitor of calpain, impacts epileptogenesis and reduces seizure burden. This suggests that inhibiting calpain could be a viable strategy to prevent epilepsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.
- Center for Dementia Research and Department of Psychiatry and Cell Biology, New York University Langone Medical Center, New York, New York, USA.
- Department of Neurology, University of California Davis School of Medicine, Sacramento, California, USA.
ORCID-Profile: Marco I González
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Lam, P. M., Rao, M. V., Nixon, R. A., & González, M. I. (2025). Calpastatin, a calpain specific inhibitor, reduce seizures in a mouse model of temporal lobe epilepsy. Epilepsia Open. https://doi.org/10.1002/epi4.70030
Vancouver
Lam PM, Rao MV, Nixon RA, González MI. Calpastatin, a calpain specific inhibitor, reduce seizures in a mouse model of temporal lobe epilepsy. Epilepsia Open. 2025. doi:10.1002/epi4.70030
BibTeX
@article{Lam2025,
author = {Lam, Philip M and Rao, Mala V and Nixon, Ralph A and González, Marco I},
title = {Calpastatin, a calpain specific inhibitor, reduce seizures in a mouse model of temporal lobe epilepsy},
journal = {Epilepsia Open},
year = {2025},
doi = {10.1002/epi4.70030}
}
EUVIMED